Off Patent
April 2027

Oxtellar XR

oxcarbazepine

Supernus Pharmaceuticals Inc

Tablet, extended release (oral) · NDA 202810

Last listed protection ends
April 13, 2027

The FDA lists 11 patents for Oxtellar XR, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 7,722,898
    Claims the drug product
  2. Patent 7,910,131
    Claims a use (U-2041)
  3. Patent 8,617,600
    Claims the drug product
  4. Patent 8,821,930
    Claims the drug product
  5. Patent 9,119,791
    Claims a use (U-2041)
  6. Patent 9,351,975
    Claims the drug product
  7. Patent 9,370,525
    Claims the drug product
  8. Patent 9,855,278
    Claims the drug product
  9. Patent 10,220,042
    Claims a use (U-2501)
  10. Patent 11,166,960
    Claims the drug product
  11. Patent 11,896,599
    Claims the drug product